Secukinumab treatment of moderate-to-severe psoriasis in children

Full-text abstracts are highly accessible and can be found in the original sources linked below.

- **ClinicalTrials.gov**: [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT03668613)
- **Full abstract**: [Full abstract](https://www.eADV.org/pdf/abstract-190785.pdf)

### Why study this study?

Secukinumab treatment of moderate-to-severe psoriasis in children

The abstract provides data on the treatment response of secukinumab in children with moderate-to-severe chronic plaque psoriasis up to 24 weeks. The study was conducted in the United States and included children aged 6 to <18 years with moderate-to-severe plaque psoriasis.

### What did this study find?

- **PASI 75/90/100**: The percentage of patients achieving a 75/90/100% reduction in their PASI score from the start of the study.
- **Week 24**: Week 24
- **Quality of life**: Quality of life was assessed using a questionnaire called the Children's Dermatology Life Quality Index (CDLQI).

The study showed secukinumab treatment provided significant, sustained improvements in disease symptoms and quality of life of children with moderate-to-severe psoriasis at disease onset.

### Summary

- **Psoriasis**: Psoriasis is a life-long debilitating disease that can affect the whole body through inflammation. It has a significant impact on children's quality of life, both physically and emotionally.
- **Secukinumab**: Secukinumab is a monoclonal antibody that targets the interleukin-17A receptor and is approved for the treatment of moderate-to-severe plaque psoriasis.
- **CDLQI**: Children's Dermatology Life Quality Index is a validated questionnaire that assesses the impact of psoriasis on quality of life.
- **PASI**: Psoriasis Area Severity Index is a measure of skin affected by psoriasis, which takes into account the area of skin affected, as well as how much redness, thickening, and scaling there is.

The safety of secukinumab was consistent with previous studies in adults with psoriasis. Further data can be found on the [ClinicalTrials.gov](https://clinicaltrials.gov/) website.

### Further information

- [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT03668613)
- [Full abstract](https://www.eADV.org/pdf/abstract-190785.pdf)
- [World Health Organization](https://apps.who.int/iris/)
- [Dermatology Life Quality Index](https://www.cardiff.ac.uk/)
- [Blair HA. Drugs. 2019;79:433–443.](https://www.cardiff.ac.uk/)
- [World Health Organization. Global report on psoriasis](https://www.cardiff.ac.uk/)

---

**Key Metrics**

- **Week 24, PASI 75**: 93%
- **Week 24, PASI 90**: 93%
- **Week 24, PASI 100**: 61%
- **Quality of life**: 84% of patients said their psoriasis had no negative impact on their quality of life with secukinumab treatment over 1 year.

---

**Glossary**

- **Psoriasis**: An immune-mediated disease that features red, sore, painful and itchy plaques that are covered by silvery or white scales. These can be seen on the skin, nails, and joints.
- **Secukinumab**: A monoclonal antibody that targets the interleukin-17A receptor and is approved for the treatment of moderate-to-severe plaque psoriasis.
- **CDLQI**: Children's Dermatology Life Quality Index is a validated questionnaire that assesses the impact of psoriasis on quality of life.
- **PASI**: Psoriasis Area Severity Index is a measure of skin affected by psoriasis, which takes into account the area of skin affected, as well as how much redness, thickening, and scaling there is.

---

**Who sponsored this study?**

Novartis Pharma AG, Basel, Switzerland

---

**Further information**

- [Further information](https://www.eADV.org/pdf/abstract-190785.pdf)
- [More on this study can be found here](https://www.eADV.org/pdf/abstract-190785.pdf)
- [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT03668613)

---

**Image Source**

- [Image](https://www.cardiff.ac.uk/)

---

**References**